Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Asoprisnil (BAY86-5294)
Asoprisnil · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | EXPERIMENTAL | - |
| Arm 3 | EXPERIMENTAL | - |
| Arm 4 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Asoprisnil (BAY86-5294) | DRUG | 5mg/day |
| Placebo | DRUG | Placebo |
Inclusion Criteria: * Patients with treatment-resistant menorrhagia scheduled for hysterectomy. Exclusion Criteria: * Organic causes of menorrhagia * Current hormone treatment
Asoprisnil is an investigational small molecule being studied for the treatment of menorrhagia, or heavy menstrual bleeding. It has been evaluated in women with treatment-resistant menorrhagia. It is not approved for any indication and remains in clinical development.
Asoprisnil targets the progesterone receptor, or PGR. It acts as a modulator of that receptor, meaning it binds the progesterone receptor and alters its signaling rather than simply blocking or activating it. This receptor-modulating activity is the basis for its study in heavy menstrual bleeding.
Asoprisnil is being developed by Bayer AG, which trades over the counter in the United States under the ticker BAYRY. Bayer holds the development program for the compound, which is also referenced as BAY86-5294.
Asoprisnil is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency for menorrhagia or any other indication. The Phase 2 program has completed its listed trial.
Asoprisnil has been studied in one Phase 2 trial, NCT00288691, titled Menorrhagia Study in Women With Treatment-resistant Menorrhagia. That trial is completed and enrolled 26 female participants aged 30 years and older. It was randomized, double-blind, and placebo-controlled.
Yes. Asoprisnil is also known as BAY86-5294, which is Bayer's internal compound designation for the same drug. Both names refer to the same investigational progesterone receptor modulator being studied for menorrhagia, so searches for either name point to the same asset.